Preference, satisfaction and critical errors with Genuair and Breezhaler inhalers in patients with COPD

a randomised, cross-over, multicentre study

Sergi Pascual, Jan Feimer, Anthony De Soyza, Jaume Sauleda Roig, John Haughney, Laura Padullés, Beatriz Seoane, Ludmyla Rekeda, Anna Ribera, Henry Chrystyn, John Andrew Francis Haughney

Research output: Contribution to journalArticle

19 Citations (Scopus)
4 Downloads (Pure)

Abstract

BACKGROUND: The specific attributes of inhaler devices can influence patient use, satisfaction and treatment compliance, and may ultimately impact on clinical outcomes in patients with chronic obstructive pulmonary disease (COPD).

AIMS: To assess patient preference, satisfaction and critical inhaler technique errors with Genuair (a multidose inhaler) and Breezhaler (a single-dose inhaler) after 2 weeks of daily use.

METHODS: Patients with COPD and moderate to severe airflow obstruction were randomised in a cross-over, open-label, multicentre study to consecutive once-daily inhalations of placebo via Genuair and Breezhaler, in addition to current COPD medication. The primary end point was the proportion of patients who preferred Genuair versus Breezhaler after 2 weeks (Patient Satisfaction and Preference Questionnaire). Other end points included overall satisfaction and correct use of the inhalers after 2 weeks, and willingness to continue with each device.

RESULTS: Of the 128 patients enrolled, 127 were included in the safety population (male n=91; mean age 67.6 years). Of the 110 of the 123 patients in the intent-to-treat population who indicated an inhaler preference, statistically significantly more patients preferred Genuair than Breezhaler (72.7 vs. 27.3%; P<0.001). Mean overall satisfaction scores were also greater for Genuair than for Breezhaler (5.9 vs. 5.3, respectively; P<0.001). After 2 weeks, there was no statistically significant difference in the number of patients who made ⩾1 critical inhaler technique error with Breezhaler than with Genuair (7.3 vs. 3.3%, respectively).

CONCLUSIONS: Patient overall preference and satisfaction was significantly higher with Genuair compared with Breezhaler. The proportion of patients making critical inhaler technique errors was low with Genuair and Breezhaler.

Original languageEnglish
Article number15018
Number of pages7
Journalnpj Primary Care Respiratory Medicine
Volume25
Early online date30 Apr 2015
DOIs
Publication statusPublished - 2015

Fingerprint

Nebulizers and Vaporizers
Cross-Over Studies
Chronic Obstructive Pulmonary Disease
Multicenter Studies
Patient Satisfaction
Patient Preference
Equipment and Supplies
Inhalation
Population
Placebos
Safety

Keywords

  • Aged
  • Cross-Over Studies
  • Equipment Design
  • Equipment Failure
  • Female
  • Humans
  • Male
  • Middle Aged
  • Nebulizers and Vaporizers
  • Patient Satisfaction
  • Pulmonary Disease, Chronic Obstructive
  • Respiratory System Agents

Cite this

Preference, satisfaction and critical errors with Genuair and Breezhaler inhalers in patients with COPD : a randomised, cross-over, multicentre study. / Pascual, Sergi; Feimer, Jan; De Soyza, Anthony; Sauleda Roig, Jaume; Haughney, John; Padullés, Laura; Seoane, Beatriz; Rekeda, Ludmyla; Ribera, Anna; Chrystyn, Henry; Haughney, John Andrew Francis.

In: npj Primary Care Respiratory Medicine, Vol. 25, 15018, 2015.

Research output: Contribution to journalArticle

Pascual, Sergi ; Feimer, Jan ; De Soyza, Anthony ; Sauleda Roig, Jaume ; Haughney, John ; Padullés, Laura ; Seoane, Beatriz ; Rekeda, Ludmyla ; Ribera, Anna ; Chrystyn, Henry ; Haughney, John Andrew Francis. / Preference, satisfaction and critical errors with Genuair and Breezhaler inhalers in patients with COPD : a randomised, cross-over, multicentre study. In: npj Primary Care Respiratory Medicine. 2015 ; Vol. 25.
@article{9753c8cdd4e340f28df05f85687eac9c,
title = "Preference, satisfaction and critical errors with Genuair and Breezhaler inhalers in patients with COPD: a randomised, cross-over, multicentre study",
abstract = "BACKGROUND: The specific attributes of inhaler devices can influence patient use, satisfaction and treatment compliance, and may ultimately impact on clinical outcomes in patients with chronic obstructive pulmonary disease (COPD).AIMS: To assess patient preference, satisfaction and critical inhaler technique errors with Genuair (a multidose inhaler) and Breezhaler (a single-dose inhaler) after 2 weeks of daily use.METHODS: Patients with COPD and moderate to severe airflow obstruction were randomised in a cross-over, open-label, multicentre study to consecutive once-daily inhalations of placebo via Genuair and Breezhaler, in addition to current COPD medication. The primary end point was the proportion of patients who preferred Genuair versus Breezhaler after 2 weeks (Patient Satisfaction and Preference Questionnaire). Other end points included overall satisfaction and correct use of the inhalers after 2 weeks, and willingness to continue with each device.RESULTS: Of the 128 patients enrolled, 127 were included in the safety population (male n=91; mean age 67.6 years). Of the 110 of the 123 patients in the intent-to-treat population who indicated an inhaler preference, statistically significantly more patients preferred Genuair than Breezhaler (72.7 vs. 27.3{\%}; P<0.001). Mean overall satisfaction scores were also greater for Genuair than for Breezhaler (5.9 vs. 5.3, respectively; P<0.001). After 2 weeks, there was no statistically significant difference in the number of patients who made ⩾1 critical inhaler technique error with Breezhaler than with Genuair (7.3 vs. 3.3{\%}, respectively).CONCLUSIONS: Patient overall preference and satisfaction was significantly higher with Genuair compared with Breezhaler. The proportion of patients making critical inhaler technique errors was low with Genuair and Breezhaler.",
keywords = "Aged, Cross-Over Studies, Equipment Design, Equipment Failure, Female, Humans, Male, Middle Aged, Nebulizers and Vaporizers, Patient Satisfaction, Pulmonary Disease, Chronic Obstructive, Respiratory System Agents",
author = "Sergi Pascual and Jan Feimer and {De Soyza}, Anthony and {Sauleda Roig}, Jaume and John Haughney and Laura Padull{\'e}s and Beatriz Seoane and Ludmyla Rekeda and Anna Ribera and Henry Chrystyn and Haughney, {John Andrew Francis}",
note = "The study was funded by Almirall S.A., Barcelona, Spain, and Forest Laboratories LLC, a subsidiary of Actavis PLC, New York, USA. Medical writing support was funded by Almirall S.A., Barcelona, Spain.",
year = "2015",
doi = "10.1038/npjpcrm.2015.18",
language = "English",
volume = "25",
journal = "npj Primary Care Respiratory Medicine",
issn = "2055-1010",
publisher = "Nature Publishing Group",

}

TY - JOUR

T1 - Preference, satisfaction and critical errors with Genuair and Breezhaler inhalers in patients with COPD

T2 - a randomised, cross-over, multicentre study

AU - Pascual, Sergi

AU - Feimer, Jan

AU - De Soyza, Anthony

AU - Sauleda Roig, Jaume

AU - Haughney, John

AU - Padullés, Laura

AU - Seoane, Beatriz

AU - Rekeda, Ludmyla

AU - Ribera, Anna

AU - Chrystyn, Henry

AU - Haughney, John Andrew Francis

N1 - The study was funded by Almirall S.A., Barcelona, Spain, and Forest Laboratories LLC, a subsidiary of Actavis PLC, New York, USA. Medical writing support was funded by Almirall S.A., Barcelona, Spain.

PY - 2015

Y1 - 2015

N2 - BACKGROUND: The specific attributes of inhaler devices can influence patient use, satisfaction and treatment compliance, and may ultimately impact on clinical outcomes in patients with chronic obstructive pulmonary disease (COPD).AIMS: To assess patient preference, satisfaction and critical inhaler technique errors with Genuair (a multidose inhaler) and Breezhaler (a single-dose inhaler) after 2 weeks of daily use.METHODS: Patients with COPD and moderate to severe airflow obstruction were randomised in a cross-over, open-label, multicentre study to consecutive once-daily inhalations of placebo via Genuair and Breezhaler, in addition to current COPD medication. The primary end point was the proportion of patients who preferred Genuair versus Breezhaler after 2 weeks (Patient Satisfaction and Preference Questionnaire). Other end points included overall satisfaction and correct use of the inhalers after 2 weeks, and willingness to continue with each device.RESULTS: Of the 128 patients enrolled, 127 were included in the safety population (male n=91; mean age 67.6 years). Of the 110 of the 123 patients in the intent-to-treat population who indicated an inhaler preference, statistically significantly more patients preferred Genuair than Breezhaler (72.7 vs. 27.3%; P<0.001). Mean overall satisfaction scores were also greater for Genuair than for Breezhaler (5.9 vs. 5.3, respectively; P<0.001). After 2 weeks, there was no statistically significant difference in the number of patients who made ⩾1 critical inhaler technique error with Breezhaler than with Genuair (7.3 vs. 3.3%, respectively).CONCLUSIONS: Patient overall preference and satisfaction was significantly higher with Genuair compared with Breezhaler. The proportion of patients making critical inhaler technique errors was low with Genuair and Breezhaler.

AB - BACKGROUND: The specific attributes of inhaler devices can influence patient use, satisfaction and treatment compliance, and may ultimately impact on clinical outcomes in patients with chronic obstructive pulmonary disease (COPD).AIMS: To assess patient preference, satisfaction and critical inhaler technique errors with Genuair (a multidose inhaler) and Breezhaler (a single-dose inhaler) after 2 weeks of daily use.METHODS: Patients with COPD and moderate to severe airflow obstruction were randomised in a cross-over, open-label, multicentre study to consecutive once-daily inhalations of placebo via Genuair and Breezhaler, in addition to current COPD medication. The primary end point was the proportion of patients who preferred Genuair versus Breezhaler after 2 weeks (Patient Satisfaction and Preference Questionnaire). Other end points included overall satisfaction and correct use of the inhalers after 2 weeks, and willingness to continue with each device.RESULTS: Of the 128 patients enrolled, 127 were included in the safety population (male n=91; mean age 67.6 years). Of the 110 of the 123 patients in the intent-to-treat population who indicated an inhaler preference, statistically significantly more patients preferred Genuair than Breezhaler (72.7 vs. 27.3%; P<0.001). Mean overall satisfaction scores were also greater for Genuair than for Breezhaler (5.9 vs. 5.3, respectively; P<0.001). After 2 weeks, there was no statistically significant difference in the number of patients who made ⩾1 critical inhaler technique error with Breezhaler than with Genuair (7.3 vs. 3.3%, respectively).CONCLUSIONS: Patient overall preference and satisfaction was significantly higher with Genuair compared with Breezhaler. The proportion of patients making critical inhaler technique errors was low with Genuair and Breezhaler.

KW - Aged

KW - Cross-Over Studies

KW - Equipment Design

KW - Equipment Failure

KW - Female

KW - Humans

KW - Male

KW - Middle Aged

KW - Nebulizers and Vaporizers

KW - Patient Satisfaction

KW - Pulmonary Disease, Chronic Obstructive

KW - Respiratory System Agents

U2 - 10.1038/npjpcrm.2015.18

DO - 10.1038/npjpcrm.2015.18

M3 - Article

VL - 25

JO - npj Primary Care Respiratory Medicine

JF - npj Primary Care Respiratory Medicine

SN - 2055-1010

M1 - 15018

ER -